HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
36:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
showed profound and long-lasting improvements in Bp. :@0.076190:0.204628:0.485160:0.204628:0.485160:0.188846:0.076190:0.188846:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.004400:0.010311:0.004551:0.009903:0.004747:0.009903:0.009177:0.009223:0.010357:0.004400:0.010326:0.009223:0.010357:0.004400:0.003024:0.009903:0.009223:0.010175:0.005020:0.003024:0.010326:0.005866:0.005125:0.003024:0.009223:0.010175:0.004400:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.014182:0.009827:0.009223:0.005125:0.005866:0.004400:0.003024:0.009223:0.004400:0.008678:0.008950:0.004188:0.004188
However, in the simplicity 3 study, where patients were :@0.076190:0.218356:0.485130:0.218356:0.485130:0.202573:0.076190:0.202573:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004853:0.003024:0.009223:0.004853:0.005125:0.009223:0.009827:0.004853:0.007529:0.003024:0.014182:0.010311:0.003024:0.003024:0.009782:0.003024:0.005125:0.008104:0.004868:0.008376:0.004853:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.004853:0.012564:0.009223:0.009827:0.004551:0.009827:0.004853:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004853:0.012564:0.009827:0.004551:0.009827:0.004188
randomised and the placebo group underwent sham :@0.076190:0.232083:0.485145:0.232083:0.485145:0.216301:0.076190:0.216301:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.006002:0.010326:0.009223:0.010357:0.006002:0.005125:0.009223:0.009827:0.005987:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.006002:0.010175:0.004551:0.009903:0.009192:0.010311:0.005987:0.009192:0.009223:0.010357:0.009827:0.004551:0.012564:0.009827:0.009223:0.005125:0.005987:0.005866:0.009223:0.010326:0.014182:0.004188
procedures, there were no differences in Bp.  Currently, :@0.076190:0.245811:0.485149:0.245821:0.485149:0.230038:0.076190:0.230028:0.010311:0.004551:0.009903:0.009782:0.009827:0.010357:0.009192:0.004551:0.009827:0.005866:0.004188:0.003750:0.005125:0.009223:0.009827:0.004551:0.009827:0.003750:0.012564:0.009827:0.004551:0.009827:0.003765:0.009223:0.009903:0.003765:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005866:0.003765:0.003024:0.009223:0.003765:0.008678:0.008950:0.004188:0.009725:0.003765:0.012292:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.003024:0.008104:0.004188:0.527322
13:@0.397400:0.240522:0.407116:0.240522:0.407116:0.231368:0.397400:0.231368:0.004858:0.004858
renal denervation is not recommended for RH.:@0.076194:0.259549:0.416085:0.259549:0.416085:0.243766:0.076194:0.243766:0.004551:0.009827:0.009223:0.010326:0.003024:0.004188:0.010357:0.009827:0.009223:0.009827:0.004551:0.008376:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.003024:0.005866:0.004188:0.009223:0.009903:0.005125:0.004188:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.004747:0.009903:0.004551:0.004188:0.009177:0.010326:0.004188
Baroreceptor stimulation is another procedure under :@0.090481:0.273276:0.485164:0.273276:0.485164:0.257494:0.090481:0.257494:0.008678:0.010326:0.004551:0.009903:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.005307:0.005866:0.005125:0.003024:0.014182:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005337:0.003024:0.005866:0.005337:0.010326:0.009223:0.009903:0.005125:0.009223:0.009827:0.004551:0.005322:0.010311:0.004551:0.009903:0.009782:0.009827:0.010357:0.009192:0.004551:0.009827:0.005322:0.009192:0.009223:0.010357:0.009827:0.004551:0.004188
investigation for RH, but it is too early to make a judge-:@0.076194:0.287004:0.480915:0.287004:0.480915:0.271221:0.076194:0.271221:0.003024:0.009223:0.008376:0.009827:0.005866:0.005125:0.003024:0.010175:0.010326:0.005125:0.003024:0.009903:0.009223:0.004747:0.004747:0.009903:0.004551:0.004747:0.009177:0.010326:0.004188:0.004747:0.010311:0.009192:0.005125:0.004747:0.003024:0.005125:0.004747:0.003024:0.005866:0.004762:0.005125:0.009903:0.009903:0.004747:0.009827:0.010326:0.004551:0.003024:0.008104:0.004747:0.005125:0.009903:0.004747:0.014182:0.010326:0.007590:0.009827:0.004747:0.010326:0.004747:0.003069:0.009192:0.010357:0.010175:0.009827:0.005020
ment on its efficacy and safety. :@0.076194:0.300731:0.310841:0.300731:0.310841:0.284949:0.076194:0.284949:0.014182:0.009827:0.009223:0.005125:0.004188:0.009903:0.009223:0.004188:0.003024:0.005125:0.005866:0.004188:0.009827:0.004747:0.003681:0.003681:0.009782:0.010326:0.009782:0.008104:0.004188:0.010326:0.009223:0.010357:0.004188:0.005866:0.010326:0.004747:0.009827:0.005125:0.008104:0.004188:0.004188
COnClusiOn:@0.076190:0.333223:0.198151:0.333223:0.198151:0.313058:0.076190:0.313058:0.014413:0.015522:0.013674:0.014413:0.008131:0.011826:0.009609:0.005174:0.015522:0.013674
RH is a common clinical problem associated with ad-:@0.076190:0.348732:0.480942:0.348732:0.480942:0.332949:0.076190:0.332949:0.009177:0.010326:0.006184:0.003024:0.005866:0.006199:0.010326:0.006184:0.009782:0.009903:0.014182:0.014182:0.009903:0.009223:0.006184:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.006199:0.010311:0.004551:0.009903:0.010311:0.003024:0.009827:0.014182:0.006184:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.006184:0.012564:0.003024:0.005125:0.009223:0.006184:0.010326:0.010357:0.005020
verse morbidity and mortality. Apparent treatment re-:@0.076190:0.362460:0.480957:0.362460:0.480957:0.346677:0.076190:0.346677:0.008376:0.009827:0.004551:0.005866:0.009827:0.006123:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.006123:0.010326:0.009223:0.010357:0.006123:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.006123:0.011188:0.010311:0.010311:0.010326:0.004551:0.009827:0.009223:0.005125:0.006108:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.006108:0.004551:0.009827:0.005020
sistance is a major issue and needs to be addressed in :@0.076190:0.376187:0.485145:0.376187:0.485145:0.360405:0.076190:0.360405:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.005095:0.003024:0.005866:0.005095:0.010326:0.005095:0.014182:0.010326:0.003069:0.009903:0.004551:0.005095:0.003024:0.005866:0.005866:0.009192:0.009827:0.005095:0.010326:0.009223:0.010357:0.005095:0.009223:0.009827:0.009827:0.010357:0.005866:0.005095:0.005125:0.009903:0.005095:0.010311:0.009827:0.005095:0.010326:0.010357:0.010357:0.004551:0.009827:0.005866:0.005866:0.009827:0.010357:0.005095:0.003024:0.009223:0.004188
the  first  instance.  Thereafter,  a  detailed  investigation :@0.076190:0.389915:0.485130:0.389915:0.485130:0.374132:0.076190:0.374132:0.005125:0.009223:0.009827:0.004188:0.003810:0.003681:0.003681:0.004551:0.005866:0.005125:0.004188:0.003825:0.003024:0.009223:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.004188:0.003810:0.006441:0.009223:0.009827:0.004551:0.009827:0.010326:0.004747:0.005125:0.009827:0.004551:0.004188:0.004188:0.003795:0.010326:0.004188:0.003825:0.010357:0.009827:0.005125:0.010326:0.003024:0.003024:0.009827:0.010357:0.004188:0.003825:0.003024:0.009223:0.008376:0.009827:0.005866:0.005125:0.003024:0.010175:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
into the reasons for resistance to therapy may include :@0.076190:0.403642:0.485145:0.403642:0.485145:0.387860:0.076190:0.387860:0.003024:0.009223:0.005125:0.009903:0.005700:0.005125:0.009223:0.009827:0.005700:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.005866:0.005700:0.004747:0.009903:0.004551:0.005700:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.005700:0.005125:0.009903:0.005700:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.005700:0.014182:0.010326:0.008104:0.005700:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004188
but should not be limited to the failure to institute life-:@0.076190:0.417370:0.480942:0.417370:0.480942:0.401587:0.076190:0.401587:0.010311:0.009192:0.005125:0.005957:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.005957:0.009223:0.009903:0.005110:0.005957:0.010311:0.009827:0.005957:0.003024:0.003024:0.014182:0.003024:0.005125:0.009827:0.010357:0.005957:0.005125:0.009903:0.005942:0.005125:0.009223:0.009827:0.005942:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005957:0.005125:0.009903:0.005942:0.003024:0.009223:0.005866:0.005125:0.003024:0.005125:0.009192:0.005125:0.009827:0.005957:0.003024:0.003024:0.004747:0.009827:0.005020
style changes, interfering drugs and secondary causes. :@0.076190:0.431097:0.485130:0.431097:0.485130:0.415315:0.076190:0.415315:0.005866:0.005125:0.008104:0.003024:0.009827:0.004657:0.009782:0.009223:0.010326:0.009223:0.010175:0.009827:0.005866:0.004188:0.004642:0.003024:0.009223:0.005125:0.009827:0.004551:0.004747:0.009827:0.004551:0.003024:0.009223:0.010175:0.004642:0.010357:0.004551:0.009192:0.010175:0.005866:0.004642:0.010326:0.009223:0.010357:0.004642:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.004642:0.009782:0.010326:0.009192:0.005866:0.009827:0.005866:0.004188:0.004188
An approach to pharmacological treatment  of RH is :@0.076190:0.444825:0.485130:0.444825:0.485130:0.429042:0.076190:0.429042:0.011188:0.009223:0.007197:0.010326:0.010311:0.010311:0.004551:0.009903:0.010326:0.009782:0.009223:0.007197:0.005125:0.009903:0.007197:0.010311:0.009223:0.010326:0.004551:0.014182:0.010326:0.009782:0.009903:0.003024:0.009903:0.010175:0.003024:0.009782:0.010326:0.003024:0.007197:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.002994:0.009903:0.004747:0.007197:0.009177:0.010326:0.007197:0.003024:0.005866:0.004188
outlined.:@0.076190:0.458552:0.140053:0.458552:0.140053:0.442770:0.076190:0.442770:0.009903:0.009192:0.005125:0.003024:0.003024:0.009223:0.009827:0.010357:0.004188
referenCes:@0.076190:0.491058:0.182628:0.491058:0.182628:0.470893:0.076190:0.470893:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.502572:0.089220:0.502572:0.089220:0.490297:0.076190:0.490297:0.006515:0.003257:0.003257
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncon-:@0.101390:0.502572:0.480956:0.502572:0.480956:0.490297:0.101390:0.490297:0.006303:0.007914:0.008032:0.007173:0.004998:0.006750:0.010807:0.003257:0.004998:0.005644:0.007173:0.008032:0.007702:0.004998:0.006961:0.003257:0.004998:0.008702:0.005644:0.007702:0.007173:0.004998:0.007138:0.008702:0.003257:0.004998:0.006750:0.003540:0.004998:0.007644:0.004998:0.002352:0.007173:0.004563:0.005903:0.002352:0.004998:0.011289:0.008702:0.003257:0.004998:0.005703:0.007644:0.003540:0.008055:0.002352:0.007173:0.008032:0.007173:0.008055:0.004998:0.006950:0.009560:0.003257:0.004998:0.007702:0.007173:0.007608:0.007702:0.007161:0.003904
trolled and apparent treatment resistant hypertension in the United :@0.101390:0.513096:0.484201:0.513096:0.484201:0.500821:0.101390:0.500821:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003104:0.008032:0.007173:0.008055:0.003116:0.008032:0.008020:0.008020:0.008032:0.003540:0.007644:0.007173:0.003986:0.003104:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003104:0.003540:0.007644:0.004563:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.003104:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003104:0.002352:0.007173:0.003104:0.003986:0.007173:0.007644:0.003104:0.007702:0.007173:0.002352:0.003986:0.007644:0.008055:0.003257
states, 1988 to 2008. :@0.101390:0.523621:0.218807:0.523621:0.218807:0.511345:0.101390:0.511345:0.005856:0.003986:0.008032:0.003986:0.007644:0.004563:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003986:0.007702:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
Circulation:@0.218807:0.523621:0.280613:0.523621:0.280613:0.511345:0.218807:0.511345:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173
. 2011;124(9):1046-58.:@0.280613:0.523621:0.400687:0.523621:0.400687:0.511345:0.280613:0.511345:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
2. :@0.076190:0.534145:0.089220:0.534145:0.089220:0.521870:0.076190:0.521870:0.006515:0.003257:0.003257
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, :@0.101390:0.534145:0.450005:0.534145:0.450005:0.521870:0.101390:0.521870:0.006303:0.007914:0.008032:0.007173:0.004469:0.006750:0.010807:0.003257:0.004469:0.005644:0.007173:0.008032:0.007702:0.004469:0.006961:0.003257:0.004457:0.005433:0.002352:0.004469:0.005668:0.003257:0.004469:0.006750:0.003540:0.004998:0.007644:0.004998:0.002352:0.007173:0.004563:0.005903:0.002352:0.004469:0.011289:0.008702:0.003257:0.004457:0.005009:0.007702:0.008055:0.007702:0.003540:0.008032:0.007173:0.004457:0.005009:0.010807:0.003257:0.004457:0.006750:0.003540:0.007702:0.007702:0.005903:0.004457:0.007138:0.008749:0.003257:0.003257
et al.:@0.451216:0.534145:0.480956:0.534145:0.480956:0.521870:0.451216:0.521870:0.007644:0.003986:0.004469:0.008032:0.002352:0.003257
 :@0.480956:0.534145:0.484213:0.534145:0.484213:0.521870:0.480956:0.521870:0.003257
prevalence of optimal treatment regimens in patients with appar-:@0.101390:0.544669:0.480956:0.544669:0.480956:0.532394:0.101390:0.532394:0.006961:0.003540:0.007644:0.006515:0.008032:0.002352:0.007644:0.007173:0.007608:0.007644:0.004069:0.007702:0.003692:0.004069:0.007702:0.008020:0.003986:0.002352:0.011030:0.008032:0.002352:0.004080:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.004069:0.003540:0.007644:0.007914:0.002352:0.011030:0.007644:0.007173:0.004563:0.004069:0.002352:0.007173:0.004080:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.004080:0.009772:0.002352:0.003986:0.007173:0.004080:0.008032:0.008020:0.008020:0.008032:0.003540:0.003904
ent  treatment-resistant  hypertension  based  on  office  blood  pres:@0.101390:0.555194:0.477040:0.555194:0.477040:0.542918:0.101390:0.542918:0.007644:0.007173:0.003986:0.003257:0.001834:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003904:0.003540:0.007644:0.004563:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.003257:0.001834:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.001834:0.008020:0.008032:0.004563:0.007644:0.008055:0.003257:0.001846:0.007702:0.007173:0.003257:0.001834:0.007702:0.003692:0.002863:0.002863:0.007608:0.007644:0.003257:0.001834:0.008020:0.002352:0.007702:0.007702:0.008055:0.003257:0.001834:0.008020:0.003540:0.007644:0.004563
-:@0.477040:0.555194:0.480944:0.555194:0.480944:0.542918:0.477040:0.542918:0.003904
sure in a community-based practice network. :@0.101390:0.565718:0.362411:0.565718:0.362411:0.553442:0.101390:0.553442:0.004563:0.007150:0.003540:0.007644:0.002999:0.002352:0.007173:0.002999:0.008032:0.002999:0.007608:0.007702:0.011030:0.011030:0.007150:0.007173:0.002352:0.003986:0.006303:0.003904:0.008020:0.008032:0.004563:0.007644:0.008055:0.002999:0.008020:0.003540:0.008032:0.007608:0.003986:0.002352:0.007608:0.007644:0.002999:0.007173:0.007644:0.003986:0.009772:0.007702:0.003540:0.005903:0.003257:0.003257
Hypertension:@0.362140:0.565718:0.436270:0.565718:0.436270:0.553442:0.362140:0.553442:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173
 (Dallas, :@0.436270:0.565718:0.484201:0.565718:0.484201:0.553442:0.436270:0.553442:0.002999:0.004339:0.008749:0.008032:0.002352:0.002352:0.008032:0.004563:0.003257:0.003257
Tex: 1979). 2013;62(4):691-7.:@0.101390:0.576242:0.257130:0.576242:0.257130:0.563967:0.101390:0.563967:0.005009:0.007644:0.005644:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
3. :@0.076190:0.586766:0.089220:0.586766:0.089220:0.574491:0.076190:0.574491:0.006515:0.003257:0.003257
Daugherty sL, powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis :@0.101390:0.586766:0.484201:0.586766:0.484201:0.574491:0.101390:0.574491:0.008749:0.008032:0.007150:0.007914:0.007173:0.007644:0.003540:0.003986:0.006303:0.002658:0.005856:0.005433:0.003257:0.002658:0.006961:0.007702:0.009772:0.007644:0.003540:0.004563:0.002658:0.005668:0.008749:0.003257:0.002658:0.010807:0.008032:0.007914:0.002352:0.008055:0.002658:0.008749:0.005668:0.003257:0.002658:0.005009:0.008032:0.006515:0.007644:0.002352:0.002669:0.008032:0.010807:0.003257:0.002658:0.010807:0.008032:0.004563:0.007702:0.007150:0.008055:0.002352:0.002669:0.005703:0.008702:0.003257:0.002658:0.010807:0.008032:0.003540:0.007914:0.007702:0.002352:0.002352:0.004563:0.003257
KL, :@0.101390:0.597291:0.120288:0.597291:0.120288:0.585015:0.101390:0.585015:0.006950:0.005433:0.003257:0.003257
et al.:@0.119758:0.597291:0.147757:0.597291:0.147757:0.585015:0.119758:0.585015:0.007644:0.003986:0.002728:0.008032:0.002352:0.003257
 Incidence and prognosis of resistant hypertension in hyper-:@0.147757:0.597291:0.480967:0.597291:0.480967:0.585015:0.147757:0.585015:0.002740:0.002658:0.007173:0.007608:0.002352:0.008055:0.007644:0.007173:0.007608:0.007644:0.002740:0.008032:0.007173:0.008055:0.002740:0.008020:0.003540:0.007702:0.007914:0.007173:0.007702:0.004563:0.002352:0.004563:0.002740:0.007702:0.003692:0.002728:0.003540:0.007644:0.004563:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.002740:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.002728:0.002352:0.007173:0.002740:0.007173:0.006303:0.008020:0.007644:0.003540:0.003904
tensive patients. :@0.101390:0.607815:0.196793:0.607815:0.196793:0.595540:0.101390:0.595540:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.003257:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257
Circulation. :@0.196793:0.607815:0.265115:0.607815:0.265115:0.595540:0.196793:0.595540:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
2012;125(13):1635-42.:@0.265115:0.607815:0.385188:0.607815:0.385188:0.595540:0.265115:0.595540:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
4. :@0.076190:0.618339:0.088984:0.618339:0.088984:0.606064:0.076190:0.606064:0.006397:0.003140:0.003257
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty sL, Dennison-:@0.101390:0.618339:0.480979:0.618339:0.480979:0.606064:0.101390:0.606064:0.009443:0.007914:0.003422:0.007526:0.006185:0.002763:0.007020:0.010689:0.003140:0.002763:0.009443:0.007914:0.002234:0.007056:0.007585:0.007032:0.007056:0.002763:0.008631:0.008584:0.003140:0.002763:0.006632:0.007914:0.005786:0.003422:0.002234:0.004445:0.002763:0.010136:0.005315:0.003140:0.002763:0.006632:0.003422:0.007585:0.007585:0.005786:0.002763:0.007020:0.008631:0.003140:0.002763:0.008631:0.007914:0.007032:0.007796:0.007056:0.007526:0.003422:0.003869:0.006185:0.002763:0.005739:0.005315:0.003140:0.002763:0.008631:0.007526:0.007056:0.007056:0.002234:0.004445:0.007585:0.007056:0.003904
Himmelfarb CR, :@0.101390:0.628864:0.192431:0.628864:0.192431:0.616588:0.101390:0.616588:0.007914:0.002234:0.010913:0.010913:0.007526:0.002234:0.003575:0.007914:0.003422:0.007902:0.003634:0.009443:0.007020:0.003140:0.003257
et al.:@0.192807:0.628864:0.221241:0.628864:0.221241:0.616588:0.192807:0.616588:0.007526:0.003869:0.003634:0.007914:0.002234:0.003257
 Resistant hypertension: Detection, evaluation, :@0.221123:0.628864:0.484236:0.628864:0.484236:0.616588:0.221123:0.616588:0.003634:0.007020:0.007526:0.004445:0.002234:0.004445:0.003869:0.007914:0.007056:0.003869:0.003634:0.007056:0.006185:0.007902:0.007526:0.003422:0.003869:0.007526:0.007056:0.004445:0.002234:0.007585:0.007056:0.003140:0.003634:0.008631:0.007526:0.003869:0.007526:0.007491:0.003869:0.002234:0.007585:0.007056:0.003140:0.003634:0.007526:0.006397:0.007914:0.002234:0.007032:0.007914:0.003869:0.002234:0.007585:0.007056:0.003257:0.003257
and management: A scientific statement srom the American Heart :@0.101390:0.639388:0.484272:0.639388:0.484272:0.627113:0.101390:0.627113:0.007914:0.007056:0.007937:0.003857:0.010913:0.007914:0.007056:0.007914:0.007796:0.007526:0.010913:0.007526:0.007056:0.003869:0.003140:0.003857:0.008584:0.003857:0.004445:0.007491:0.002234:0.007526:0.007056:0.003869:0.002234:0.002805:0.002805:0.007491:0.003857:0.004445:0.003869:0.007914:0.003869:0.007526:0.010913:0.007526:0.007056:0.003869:0.003857:0.004445:0.003422:0.007585:0.010913:0.003857:0.003869:0.007056:0.007526:0.003857:0.008584:0.010913:0.007526:0.003422:0.002234:0.007491:0.007914:0.007056:0.003857:0.007914:0.007526:0.007914:0.003422:0.003986:0.003257
Association. :@0.101390:0.649912:0.171229:0.649912:0.171229:0.637637:0.101390:0.637637:0.008584:0.004445:0.004445:0.007585:0.007491:0.002234:0.007914:0.003869:0.002234:0.007585:0.007056:0.003140:0.003257
Hypertension:@0.171111:0.649912:0.243948:0.649912:0.243948:0.637637:0.171111:0.637637:0.007914:0.006185:0.007902:0.007526:0.003422:0.003869:0.007526:0.007056:0.004445:0.002234:0.007585:0.007173
 (Dallas, Tex: 1979). 2018;72(5):e53-e90.:@0.243830:0.649912:0.458343:0.649912:0.458343:0.637637:0.243830:0.637637:0.003140:0.004222:0.008631:0.007914:0.002234:0.002234:0.007914:0.004445:0.003140:0.003140:0.004892:0.007526:0.005527:0.003140:0.003140:0.006397:0.006397:0.006397:0.006397:0.004222:0.003140:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.006397:0.006397:0.004222:0.006397:0.004222:0.003140:0.007526:0.006397:0.006397:0.003786:0.007526:0.006397:0.006397:0.003257
5. :@0.076202:0.660437:0.089231:0.660437:0.089231:0.648161:0.076202:0.648161:0.006515:0.003257:0.003257
Moosa Ms, Kuttschreuter Ls, Rayner BL. Evaluation and manage-:@0.101402:0.660437:0.480956:0.660437:0.480956:0.648161:0.101402:0.648161:0.010807:0.007702:0.007702:0.004563:0.008032:0.004939:0.010807:0.005856:0.003257:0.004939:0.006950:0.007150:0.003986:0.003986:0.004563:0.007608:0.007173:0.003540:0.007644:0.007150:0.003986:0.007644:0.003540:0.004927:0.005433:0.005856:0.003257:0.004939:0.007138:0.008032:0.006303:0.007173:0.007644:0.003540:0.004939:0.006750:0.005433:0.003257:0.004939:0.006303:0.006515:0.008032:0.002352:0.007150:0.008032:0.003986:0.002352:0.007702:0.007173:0.004951:0.008032:0.007173:0.008055:0.004939:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.003904
ment  of  patients  referred  to  a tertiary-level  hypertension  clinic :@0.101402:0.670961:0.484201:0.670961:0.484201:0.658686:0.101402:0.658686:0.011030:0.007644:0.007173:0.003986:0.003257:0.003622:0.007702:0.003692:0.003257:0.003622:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.003622:0.003540:0.007644:0.003692:0.007644:0.003540:0.003540:0.007644:0.008055:0.003257:0.003610:0.003986:0.007702:0.003257:0.003622:0.008032:0.006891:0.003986:0.007644:0.003540:0.003986:0.002352:0.008032:0.003540:0.006303:0.003904:0.002352:0.007644:0.006515:0.007644:0.002352:0.003257:0.003622:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.003622:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.003257
in Cape Town,  south  Africa. :@0.101402:0.681485:0.284470:0.681485:0.284470:0.669210:0.101402:0.669210:0.002352:0.007173:0.008772:0.009560:0.008032:0.008020:0.007644:0.008772:0.005009:0.007702:0.009772:0.007173:0.003257:0.003257:0.005503:0.005856:0.007702:0.007150:0.003986:0.007173:0.003257:0.005503:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.003257:0.003257
South African  Medical Journal. :@0.289985:0.681485:0.484225:0.681485:0.484225:0.669210:0.289985:0.669210:0.005856:0.007702:0.007150:0.003986:0.007161:0.008772:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.003257:0.005503:0.010807:0.007644:0.008055:0.002352:0.007608:0.008032:0.002352:0.008772:0.005668:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257:0.003257
2016;106(8):797-800.:@0.101402:0.692010:0.214961:0.692010:0.214961:0.679734:0.101402:0.679734:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
6. :@0.076202:0.702534:0.089231:0.702534:0.089231:0.690259:0.076202:0.690259:0.006515:0.003257:0.003257
Vrijens B, Vincze G, Kristanto p, Urquhart J, Burnier M. Adherence to :@0.101402:0.702534:0.484236:0.702534:0.484236:0.690259:0.101402:0.690259:0.008255:0.003540:0.002352:0.002387:0.007644:0.007173:0.004563:0.003316:0.006750:0.003257:0.003316:0.008255:0.002352:0.007173:0.007608:0.004998:0.007644:0.003316:0.010254:0.003257:0.003316:0.006950:0.003540:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.007702:0.003316:0.006961:0.003257:0.003316:0.007702:0.003540:0.008020:0.007150:0.007173:0.008032:0.003540:0.003986:0.003316:0.005668:0.003257:0.003316:0.006750:0.007150:0.003540:0.007173:0.002352:0.007644:0.003540:0.003316:0.010807:0.003257:0.003316:0.008702:0.008055:0.007173:0.007644:0.003540:0.007644:0.007173:0.007608:0.007644:0.003304:0.003986:0.007702:0.003257
prescribed antihypertensive drug treatments: Longitudinal study of :@0.101402:0.713058:0.484225:0.713058:0.484225:0.700783:0.101402:0.700783:0.008020:0.003540:0.007644:0.004563:0.007608:0.003540:0.002352:0.008020:0.007644:0.008055:0.003645:0.008032:0.007173:0.003986:0.002352:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.003645:0.008055:0.003540:0.007150:0.007914:0.003645:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.004563:0.003257:0.003634:0.005433:0.007702:0.007173:0.007914:0.002352:0.003986:0.007150:0.008055:0.002352:0.007173:0.008032:0.002352:0.003645:0.004563:0.003986:0.007150:0.008055:0.006303:0.003645:0.007702:0.003692:0.003257
electronically compiled dosing histories. :@0.101402:0.723583:0.330743:0.723583:0.330743:0.711307:0.101402:0.711307:0.007644:0.002352:0.007644:0.007608:0.003986:0.003540:0.007702:0.007173:0.002352:0.007608:0.008032:0.002352:0.002352:0.006303:0.003257:0.007608:0.007702:0.011030:0.008020:0.002352:0.002352:0.007644:0.008055:0.003269:0.008055:0.007702:0.004563:0.002352:0.007173:0.007914:0.003257:0.007173:0.002352:0.004563:0.003986:0.007702:0.003540:0.002352:0.007644:0.004563:0.003257:0.003257
BMJ (clinical research ed). :@0.330743:0.723583:0.484213:0.723583:0.484213:0.711307:0.330743:0.711307:0.006750:0.010807:0.005668:0.003257:0.004339:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003269:0.003540:0.007644:0.004563:0.007644:0.008032:0.003540:0.007608:0.007173:0.003257:0.007644:0.008055:0.004339:0.003257:0.003257
2008;336(7653):1114-7.:@0.101402:0.734107:0.227991:0.734107:0.227991:0.721832:0.101402:0.721832:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
7. :@0.076202:0.744631:0.089231:0.744631:0.089231:0.732356:0.076202:0.732356:0.006515:0.003257:0.003257
Jones EsW, Lesosky M, Blockman M, Castel s, Decloedt EH, schwa-:@0.101402:0.744631:0.480956:0.744631:0.480956:0.732356:0.101402:0.732356:0.005668:0.007702:0.007173:0.007644:0.004563:0.003434:0.006303:0.005856:0.011289:0.003257:0.003434:0.005433:0.007644:0.004563:0.007702:0.004563:0.005903:0.006303:0.003445:0.010807:0.003257:0.003434:0.006750:0.002352:0.007702:0.007608:0.005903:0.011030:0.008032:0.007173:0.003445:0.010807:0.003257:0.003434:0.009560:0.008032:0.004563:0.003986:0.007644:0.002352:0.003445:0.005856:0.003257:0.003434:0.008749:0.007644:0.007608:0.002352:0.007702:0.007644:0.008055:0.003986:0.003434:0.006303:0.008032:0.003257:0.003445:0.005856:0.007608:0.007173:0.009772:0.008032:0.003904
ger sLU, :@0.101402:0.755156:0.149909:0.755156:0.149909:0.742880:0.101402:0.742880:0.007914:0.007644:0.003540:0.003904:0.005856:0.005433:0.007702:0.003257:0.003257
et al.:@0.150556:0.755156:0.179731:0.755156:0.179731:0.742880:0.150556:0.742880:0.007644:0.003986:0.003904:0.008032:0.002352:0.003257
 Therapeutic drug monitoring of amlodipine and the :@0.179731:0.755156:0.484236:0.755156:0.484236:0.742880:0.179731:0.742880:0.003904:0.005009:0.007173:0.007644:0.003540:0.008032:0.008020:0.007644:0.007150:0.003986:0.002352:0.007608:0.003904:0.008055:0.003540:0.007150:0.007914:0.003904:0.011030:0.007702:0.007173:0.002352:0.003986:0.007702:0.003540:0.002352:0.007173:0.007914:0.003904:0.007702:0.003692:0.003904:0.008032:0.011030:0.002352:0.007702:0.008055:0.002352:0.008020:0.002352:0.007173:0.007644:0.003916:0.008032:0.007173:0.008055:0.003904:0.003986:0.007173:0.007644:0.003257
Z-FHL/HHL ratio: Adherence tools in patients referred for apparent :@0.101402:0.765680:0.484225:0.765680:0.484225:0.753404:0.101402:0.753404:0.005644:0.003904:0.005703:0.008032:0.005433:0.005139:0.008032:0.008032:0.005433:0.004245:0.003540:0.008032:0.003986:0.002352:0.007702:0.003257:0.004233:0.008702:0.008055:0.007173:0.007644:0.003540:0.007644:0.007173:0.007608:0.007644:0.004233:0.003986:0.007702:0.007702:0.002352:0.004563:0.004233:0.002352:0.007173:0.004245:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.004245:0.003540:0.007644:0.003692:0.007644:0.003540:0.003540:0.007644:0.008055:0.004233:0.003692:0.007702:0.003540:0.004233:0.008032:0.008020:0.008020:0.008032:0.003540:0.007644:0.007173:0.003986:0.003257
treatment-resistant  hypertension.:@0.101402:0.776204:0.291008:0.776204:0.291008:0.763929:0.101402:0.763929:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003904:0.003540:0.007644:0.004563:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.003257:0.003057:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257
 South  African  Medical Journal. :@0.290997:0.776204:0.484225:0.776204:0.484225:0.763929:0.290997:0.763929:0.006326:0.005856:0.007702:0.007150:0.003986:0.007173:0.003257:0.003057:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.003257:0.003057:0.010807:0.007644:0.008055:0.002352:0.007608:0.008032:0.002352:0.006326:0.005668:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257:0.003257
2017;107(10):887-91.:@0.101402:0.786729:0.214961:0.786729:0.214961:0.774453:0.101402:0.774453:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
8. :@0.076202:0.797253:0.089231:0.797253:0.089231:0.784977:0.076202:0.784977:0.006515:0.003257:0.003257
Myers MG, Godwin M, Dawes M, Kiss A, Tobe sW, Kaczorowski J. :@0.101402:0.797253:0.484225:0.797253:0.484225:0.784977:0.101402:0.784977:0.010807:0.006303:0.007644:0.003540:0.004563:0.004821:0.010807:0.010254:0.003257:0.004821:0.010254:0.007702:0.008055:0.009772:0.002352:0.007173:0.004821:0.010807:0.003257:0.004821:0.008749:0.008032:0.009772:0.007644:0.004563:0.004821:0.010807:0.003257:0.004821:0.006950:0.002352:0.004563:0.004563:0.004821:0.008702:0.003257:0.004810:0.005009:0.007702:0.008020:0.007644:0.004798:0.005856:0.011289:0.003257:0.004821:0.006950:0.008032:0.007608:0.004998:0.007702:0.003540:0.007702:0.009772:0.004563:0.005903:0.002352:0.004810:0.005668:0.003257:0.003257
Measurement of blood pressure in the office: Recognizing the prob:@0.101402:0.807777:0.477063:0.807777:0.477063:0.795502:0.101402:0.795502:0.010807:0.007644:0.008032:0.004563:0.007150:0.003540:0.007644:0.011030:0.007644:0.007173:0.003986:0.002728:0.007702:0.003692:0.002728:0.008020:0.002352:0.007702:0.007702:0.008055:0.002728:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.002728:0.002352:0.007173:0.002728:0.003986:0.007173:0.007644:0.002728:0.007702:0.003692:0.002863:0.002863:0.007608:0.007644:0.003257:0.002728:0.007138:0.007644:0.007608:0.007702:0.007914:0.007173:0.002352:0.004998:0.002352:0.007173:0.007914:0.002728:0.003986:0.007173:0.007644:0.002728:0.008020:0.003540:0.007702:0.008020
-:@0.477063:0.807777:0.480967:0.807777:0.480967:0.795502:0.477063:0.795502:0.003904
lem and proposing the solution. :@0.101402:0.818301:0.284000:0.818301:0.284000:0.806026:0.101402:0.806026:0.002352:0.007644:0.011030:0.003257:0.008032:0.007173:0.008055:0.003257:0.008020:0.003540:0.007702:0.008020:0.007702:0.004563:0.002352:0.007173:0.007914:0.003257:0.003986:0.007173:0.007644:0.003257:0.004563:0.007702:0.002352:0.007150:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
Hypertension.:@0.283976:0.818301:0.361364:0.818301:0.361364:0.806026:0.283976:0.806026:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257
 2010;55(2):195-200.:@0.361364:0.818301:0.471666:0.818301:0.471666:0.806026:0.361364:0.806026:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
9. :@0.076202:0.828826:0.089231:0.828826:0.089231:0.816550:0.076202:0.816550:0.006515:0.003257:0.003257
Cooper CJ, Murphy Tp, Cutlip DE, Jamerson K, Henrich W, Reid DM, :@0.101402:0.828826:0.484225:0.828826:0.484225:0.816550:0.101402:0.816550:0.009560:0.007702:0.007702:0.008020:0.007644:0.003540:0.003210:0.009560:0.005668:0.003257:0.003210:0.010807:0.007150:0.003540:0.008020:0.007173:0.006303:0.003210:0.005009:0.006961:0.003257:0.003210:0.009560:0.007150:0.003986:0.002352:0.002352:0.008020:0.003222:0.008749:0.006303:0.003257:0.003222:0.005668:0.008032:0.011030:0.007644:0.003540:0.004563:0.007702:0.007173:0.003210:0.006950:0.003257:0.003210:0.008032:0.007644:0.007173:0.003540:0.002352:0.007608:0.007173:0.003210:0.011289:0.003257:0.003210:0.007138:0.007644:0.002352:0.008055:0.003210:0.008749:0.010807:0.003257:0.003257
et al.:@0.101402:0.839350:0.130060:0.839350:0.130060:0.827075:0.101402:0.827075:0.007644:0.003986:0.003387:0.008032:0.002352:0.003257
 stenting and medical therapy for atherosclerotic renal-artery :@0.130060:0.839350:0.484225:0.839350:0.484225:0.827075:0.130060:0.827075:0.003398:0.005856:0.003986:0.007644:0.007173:0.003986:0.002352:0.007173:0.007914:0.003387:0.008032:0.007173:0.008055:0.003398:0.011030:0.007644:0.008055:0.002352:0.007608:0.008032:0.002352:0.003398:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003387:0.003692:0.007702:0.003540:0.003387:0.008032:0.003986:0.007173:0.007644:0.003540:0.007702:0.004563:0.007608:0.002352:0.007644:0.003540:0.007702:0.003986:0.002352:0.007608:0.003387:0.003540:0.007644:0.007173:0.008032:0.002352:0.003904:0.008032:0.003540:0.003986:0.007644:0.003540:0.006303:0.003257
stenosis. :@0.101402:0.849874:0.150462:0.849874:0.150462:0.837599:0.101402:0.837599:0.004563:0.003986:0.007644:0.007173:0.007702:0.004563:0.002352:0.004563:0.003257:0.003257
The New England Journal of Medicine.:@0.150462:0.849874:0.369595:0.849874:0.369595:0.837599:0.150462:0.837599:0.005009:0.007173:0.007644:0.003257:0.008702:0.007644:0.009772:0.003257:0.006303:0.007173:0.007914:0.002352:0.008032:0.007173:0.008055:0.003257:0.005668:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257:0.007702:0.003692:0.003257:0.010807:0.007644:0.008055:0.002352:0.007608:0.002352:0.007173:0.007644:0.003257
 2014;370(1):13-22.:@0.369572:0.849874:0.473359:0.849874:0.473359:0.837599:0.369572:0.837599:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
10.  Banegas JR, Ruilope LM, de la sierra A, Vinyoles E, Gorostidi M, de :@0.076202:0.860399:0.484201:0.860399:0.484201:0.848123:0.076202:0.848123:0.006515:0.006515:0.003257:0.003257:0.005656:0.006750:0.008032:0.007173:0.007644:0.007914:0.008032:0.004563:0.003869:0.005668:0.007138:0.003257:0.003857:0.007138:0.007150:0.002352:0.002352:0.007702:0.008020:0.007644:0.003869:0.005433:0.010807:0.003257:0.003857:0.008055:0.007644:0.003857:0.002352:0.008032:0.003869:0.005856:0.002352:0.007644:0.003540:0.003540:0.008032:0.003857:0.008702:0.003257:0.003857:0.008255:0.002352:0.007173:0.006303:0.007702:0.002352:0.007644:0.004563:0.003869:0.006303:0.003257:0.003869:0.010254:0.007702:0.003540:0.007702:0.004563:0.003986:0.002352:0.008055:0.002352:0.003857:0.010807:0.003257:0.003857:0.008055:0.007644:0.003257
la Cruz JJ, :@0.101402:0.870923:0.163809:0.870923:0.163809:0.858648:0.101402:0.858648:0.002352:0.008032:0.004469:0.009560:0.003540:0.007150:0.004998:0.004457:0.005668:0.005668:0.003257:0.003257
et al. :@0.165020:0.870923:0.198004:0.870923:0.198004:0.858648:0.165020:0.858648:0.007644:0.003986:0.004457:0.008032:0.002352:0.003257:0.003257
Clinic versus daytime ambulatory blood pressure :@0.199216:0.870923:0.484225:0.870923:0.484225:0.858648:0.199216:0.858648:0.009560:0.002352:0.002352:0.007173:0.002352:0.007608:0.004469:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.004469:0.008055:0.008032:0.006303:0.003986:0.002352:0.011030:0.007644:0.004469:0.008032:0.011030:0.008020:0.007150:0.002352:0.008032:0.003986:0.007702:0.003540:0.006303:0.004469:0.008020:0.002352:0.007702:0.007702:0.008055:0.004469:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.003257
difference in hypertensive patients: The impact of age and clinic :@0.101402:0.881447:0.484201:0.881447:0.484201:0.869172:0.101402:0.869172:0.008055:0.002352:0.003692:0.003692:0.007644:0.003540:0.007644:0.007173:0.007608:0.007644:0.004539:0.002352:0.007173:0.004539:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.004539:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.004539:0.005009:0.007173:0.007644:0.004539:0.002352:0.011030:0.008020:0.008032:0.007608:0.003986:0.004551:0.007702:0.003692:0.004539:0.008032:0.007914:0.007644:0.004539:0.008032:0.007173:0.008055:0.004539:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.003257
blood pressure. :@0.101402:0.891972:0.191666:0.891972:0.191666:0.879696:0.101402:0.879696:0.008020:0.002352:0.007702:0.007702:0.008055:0.003257:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.003257:0.003257
Hypertension.:@0.191654:0.891972:0.269042:0.891972:0.269042:0.879696:0.191654:0.879696:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257
 2017;69(2):211-9.:@0.269042:0.891972:0.366315:0.891972:0.366315:0.879696:0.269042:0.879696:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.003257
11.  Williams B, MacDonald TM, Morant sV, Webb DJ, sever p, McInnes :@0.076202:0.902496:0.484236:0.902496:0.484236:0.890221:0.076202:0.890221:0.006515:0.006515:0.003257:0.003257:0.005656:0.011289:0.002352:0.002352:0.002352:0.002352:0.008032:0.011030:0.004563:0.003751:0.006750:0.003257:0.003739:0.010807:0.008032:0.007608:0.008749:0.007702:0.007173:0.008032:0.002352:0.008055:0.003739:0.005009:0.010807:0.003257:0.003728:0.010807:0.007702:0.003540:0.008032:0.007161:0.003986:0.003739:0.005856:0.008255:0.003257:0.003739:0.011289:0.007644:0.008020:0.008020:0.003739:0.008749:0.005668:0.003257:0.003739:0.005856:0.007644:0.006515:0.007644:0.003540:0.003739:0.006961:0.003257:0.003728:0.010807:0.007608:0.002658:0.007173:0.007173:0.007644:0.004563:0.003257
GT, :@0.101402:0.913020:0.123180:0.913020:0.123180:0.900745:0.101402:0.900745:0.010254:0.005009:0.003257:0.003257
et al.:@0.127096:0.913020:0.159540:0.913020:0.159540:0.900745:0.127096:0.900745:0.007644:0.003986:0.007173:0.008032:0.002352:0.003257
 Endocrine  and haemodynamic changes in resistant :@0.159540:0.913020:0.484236:0.913020:0.484236:0.900745:0.159540:0.900745:0.007173:0.006303:0.007173:0.008055:0.007702:0.007608:0.003540:0.002352:0.007173:0.007644:0.003257:0.003904:0.008032:0.007173:0.008055:0.007173:0.007173:0.008032:0.007644:0.011030:0.007702:0.008055:0.006303:0.007173:0.008032:0.011030:0.002352:0.007608:0.007173:0.007608:0.007173:0.008032:0.007173:0.007914:0.007644:0.004563:0.007173:0.002352:0.007173:0.007173:0.003540:0.007644:0.004563:0.002352:0.004563:0.003986:0.008032:0.007173:0.003986:0.003257
hypertension,  and  blood  pressure  responses  to  spironolactone  or :@0.101402:0.923545:0.484225:0.923545:0.484225:0.911269:0.101402:0.911269:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.003257:0.001799:0.008032:0.007173:0.008055:0.003257:0.001799:0.008020:0.002352:0.007702:0.007702:0.008055:0.003257:0.001799:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.003257:0.001799:0.003540:0.007644:0.004563:0.008020:0.007702:0.007173:0.004563:0.007644:0.004563:0.003257:0.001799:0.003986:0.007702:0.003257:0.001799:0.004563:0.008020:0.002352:0.003540:0.007702:0.007173:0.007702:0.002352:0.008032:0.007608:0.003986:0.007702:0.007173:0.007644:0.003257:0.001799:0.007702:0.003540:0.003257
amiloride: The pATHWAY-2 mechanisms substudies. :@0.101402:0.934069:0.391985:0.934069:0.391985:0.921794:0.101402:0.921794:0.008032:0.011030:0.002352:0.002352:0.007702:0.003540:0.002352:0.008055:0.007644:0.003257:0.003163:0.005009:0.007173:0.007644:0.003163:0.006961:0.008702:0.005009:0.008032:0.011289:0.008702:0.006961:0.003904:0.006515:0.003151:0.011030:0.007644:0.007608:0.007173:0.008032:0.007173:0.002352:0.004563:0.011030:0.004563:0.003163:0.004563:0.007150:0.008020:0.004563:0.003986:0.007150:0.008055:0.002352:0.007644:0.004563:0.003257:0.003257
The Lancet Dia-:@0.391891:0.934069:0.480956:0.934069:0.480956:0.921794:0.391891:0.921794:0.005009:0.007173:0.007644:0.003163:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003163:0.008749:0.002352:0.008032:0.003904
betes & Endocrinology. :@0.101402:0.944593:0.237069:0.944593:0.237069:0.932318:0.101402:0.932318:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.008902:0.003257:0.006303:0.007173:0.008055:0.007702:0.007608:0.003540:0.002352:0.007173:0.007702:0.002352:0.007702:0.007914:0.006303:0.003257:0.003257
2018;6(6):464-75.:@0.237057:0.944593:0.331072:0.944593:0.331072:0.932318:0.237057:0.932318:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
12.  Akintunde A, Nondi J, Gogo K, Jones EsW, Rayner BL, Hackam DG, :@0.519067:0.201937:0.927066:0.201937:0.927066:0.189662:0.519067:0.189662:0.006515:0.006515:0.003257:0.003257:0.005656:0.008702:0.005903:0.002352:0.007173:0.003986:0.007150:0.007173:0.008055:0.007644:0.003375:0.008702:0.003257:0.003375:0.008702:0.007702:0.007173:0.008055:0.002352:0.003375:0.005668:0.003257:0.003375:0.010254:0.007702:0.007914:0.007702:0.003375:0.006950:0.003257:0.003375:0.005668:0.007702:0.007173:0.007644:0.004563:0.003375:0.006303:0.005856:0.011289:0.003257:0.003375:0.007138:0.008032:0.006303:0.007173:0.007644:0.003540:0.003375:0.006750:0.005433:0.003257:0.003375:0.008032:0.008032:0.007608:0.005903:0.008032:0.011030:0.003387:0.008749:0.010254:0.003257:0.003257
et al. :@0.544267:0.212839:0.575747:0.212839:0.575747:0.200564:0.544267:0.200564:0.007644:0.003986:0.002952:0.008032:0.002352:0.003257:0.003257
physiological phenotyping for personalized therapy of uncon-:@0.575453:0.212839:0.923832:0.212839:0.923832:0.200564:0.575453:0.200564:0.006961:0.007173:0.006303:0.004563:0.002352:0.007702:0.002352:0.007702:0.007914:0.002352:0.007608:0.008032:0.002352:0.002963:0.008020:0.007173:0.007644:0.007173:0.007702:0.003986:0.006303:0.008020:0.002352:0.007173:0.007914:0.002952:0.003692:0.007702:0.003540:0.002952:0.008020:0.007644:0.003540:0.004563:0.007702:0.007173:0.008032:0.002352:0.002352:0.004998:0.007644:0.008055:0.002963:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.002952:0.007702:0.003692:0.002952:0.007150:0.007173:0.007608:0.007702:0.007185:0.003904
trolled  hypertension  in Africa. :@0.544267:0.223740:0.719198:0.223740:0.719198:0.211465:0.544267:0.211465:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003257:0.002093:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.002093:0.002352:0.007173:0.005362:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.003257:0.003257
American  Journal  of  Hypertension. :@0.721291:0.223740:0.927078:0.223740:0.927078:0.211465:0.721291:0.211465:0.008702:0.011030:0.007644:0.003540:0.002352:0.007608:0.008032:0.007173:0.003257:0.002093:0.005668:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257:0.002093:0.007702:0.003692:0.003257:0.002093:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.003257
2017;30(9):923-30.:@0.544267:0.234642:0.644797:0.234642:0.644797:0.222366:0.544267:0.222366:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
13.  Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, :@0.519067:0.245543:0.927137:0.245543:0.927137:0.233268:0.519067:0.233268:0.006397:0.006397:0.003140:0.003257:0.006009:0.006632:0.007056:0.007914:0.003869:0.003869:0.002857:0.008631:0.005315:0.003140:0.002857:0.006832:0.007914:0.007056:0.007937:0.004880:0.007914:0.003422:0.002234:0.002857:0.008631:0.006185:0.003140:0.002857:0.010101:0.004010:0.008584:0.007526:0.002234:0.002234:0.002234:0.002857:0.011171:0.011171:0.003140:0.002857:0.008631:0.004010:0.008584:0.007796:0.007585:0.004445:0.003869:0.002234:0.007056:0.007585:0.002857:0.007020:0.003140:0.002857:0.005586:0.002234:0.007914:0.007491:0.005786:0.002857:0.005550:0.010689:0.003140:0.002857:0.006832:0.007914:0.003869:0.004880:0.007526:0.007056:0.002857:0.006632:0.004892:0.003257:0.003257
et al. :@0.544267:0.256445:0.574947:0.256445:0.574947:0.244169:0.544267:0.244169:0.007526:0.003869:0.002740:0.007914:0.002234:0.003140:0.003257
A controlled trial of renal denervation for resistant hypertension.:@0.574430:0.256445:0.923856:0.256445:0.923856:0.244169:0.574430:0.244169:0.008584:0.002740:0.007491:0.007585:0.007056:0.003869:0.003422:0.007585:0.002234:0.002234:0.007526:0.007937:0.002740:0.003869:0.003422:0.002234:0.007914:0.002234:0.002740:0.007585:0.003575:0.002740:0.003422:0.007526:0.007056:0.007914:0.002234:0.002740:0.007937:0.007526:0.007056:0.007526:0.003422:0.006397:0.007914:0.003869:0.002234:0.007585:0.007056:0.002740:0.003575:0.007585:0.003422:0.002740:0.003422:0.007526:0.004445:0.002234:0.004445:0.003869:0.007914:0.007056:0.003869:0.002740:0.007056:0.006185:0.007902:0.007526:0.003422:0.003869:0.007526:0.007056:0.004445:0.002234:0.007585:0.007056:0.003257
 :@0.923832:0.256445:0.927090:0.256445:0.927090:0.244169:0.923832:0.244169:0.003257
The New England Journal of Medicine.:@0.544267:0.267346:0.759285:0.267346:0.759285:0.255071:0.544267:0.255071:0.004892:0.007056:0.007526:0.003140:0.008584:0.007526:0.009654:0.003140:0.006185:0.007056:0.007796:0.002234:0.007914:0.007056:0.007937:0.003140:0.005550:0.007585:0.007032:0.003422:0.007056:0.007914:0.002234:0.003140:0.007585:0.003575:0.003140:0.010689:0.007526:0.007937:0.002234:0.007491:0.002234:0.007056:0.007526:0.003257
 2014;370(15):1393-401.:@0.759168:0.267346:0.886426:0.267346:0.886426:0.255071:0.759168:0.255071:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.006397:0.006397:0.006397:0.004222:0.006397:0.006397:0.004222:0.003140:0.006397:0.006397:0.006397:0.006397:0.003786:0.006397:0.006397:0.006397:0.003257
Table 3. Renin- and aldosterone-profiling for RH:@0.077030:0.088780:0.420535:0.088780:0.420535:0.072281:0.077030:0.072281:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.008769:0.009676:0.009071:0.003629:0.009071:0.006350:0.004233:0.009979:0.009071:0.009979:0.004233:0.009979:0.003629:0.009979:0.009676:0.006652:0.004536:0.009676:0.004838:0.009676:0.009071:0.009676:0.006350:0.009979:0.004838:0.009676:0.003931:0.003931:0.003629:0.003629:0.009071:0.009979:0.004233:0.004233:0.009676:0.004838:0.004233:0.008769:0.010281
Condition:@0.082070:0.107628:0.145234:0.107628:0.145234:0.092963:0.082070:0.092963:0.010483:0.008601:0.008063:0.008870:0.003225:0.004032:0.003225:0.008601:0.008063
Plasma renin level:@0.293763:0.107628:0.411759:0.107628:0.411759:0.092963:0.293763:0.092963:0.007526:0.003225:0.008870:0.005913:0.012633:0.008870:0.003763:0.004301:0.008601:0.008063:0.003225:0.008063:0.003763:0.003225:0.008601:0.007526:0.008601:0.003225
Plasma aldosterone:@0.505457:0.107628:0.633935:0.107628:0.633935:0.092963:0.505457:0.092963:0.007526:0.003225:0.008870:0.005913:0.012633:0.008870:0.003763:0.008870:0.003225:0.008870:0.008601:0.005913:0.004032:0.008601:0.004301:0.008601:0.008063:0.008601
Primary treatment:@0.717150:0.107628:0.832727:0.107628:0.832727:0.092963:0.717150:0.092963:0.007526:0.004301:0.003225:0.012633:0.008870:0.004301:0.007795:0.003763:0.004032:0.004301:0.008601:0.008870:0.004032:0.012633:0.008601:0.008063:0.004032
primary aldosteronism:@0.082070:0.123022:0.223450:0.123022:0.223450:0.108993:0.082070:0.108993:0.007956:0.004045:0.002688:0.012606:0.009179:0.004045:0.007203:0.003723:0.009179:0.002688:0.009206:0.008803:0.005214:0.004556:0.008735:0.004045:0.008803:0.008198:0.002688:0.005214:0.012606
low:@0.293763:0.123022:0.316422:0.123022:0.316422:0.108993:0.293763:0.108993:0.002688:0.008803:0.011168
Normal to high:@0.505457:0.123022:0.601654:0.123022:0.601654:0.108993:0.505457:0.108993:0.009945:0.008803:0.004045:0.012606:0.009179:0.002688:0.003723:0.004556:0.008803:0.003723:0.008198:0.002688:0.009045:0.008198
spironolactone, rarely surgery:@0.717150:0.123022:0.909921:0.123022:0.909921:0.108993:0.717150:0.108993:0.006693:0.009165:0.002688:0.004045:0.008803:0.008198:0.008803:0.002688:0.009179:0.008695:0.004556:0.008803:0.008198:0.008735:0.003723:0.003723:0.004045:0.009179:0.004045:0.008735:0.002688:0.007203:0.003723:0.005214:0.008171:0.004045:0.009045:0.008735:0.004045:0.007203
Liddle phenotype:@0.082070:0.138416:0.197284:0.138416:0.197284:0.124387:0.082070:0.124387:0.006209:0.002688:0.009206:0.009206:0.002688:0.008735:0.003723:0.009165:0.008198:0.008735:0.008198:0.008803:0.004556:0.007203:0.009165:0.008735
low:@0.293763:0.138416:0.316422:0.138416:0.316422:0.124387:0.293763:0.124387:0.002688:0.008803:0.011168
Low:@0.505457:0.138416:0.531636:0.138416:0.531636:0.124387:0.505457:0.124387:0.006209:0.008803:0.011168
Amiloride:@0.717150:0.138416:0.778554:0.138416:0.778554:0.124387:0.717150:0.124387:0.009945:0.012606:0.002688:0.002688:0.008803:0.004045:0.002688:0.009206:0.008735
Renal, renovascular, other:@0.082070:0.153810:0.252653:0.153810:0.252653:0.139781:0.082070:0.139781:0.008158:0.008735:0.008198:0.009179:0.002688:0.003723:0.003723:0.004045:0.008735:0.008198:0.008803:0.007445:0.009179:0.005214:0.008695:0.008171:0.002688:0.009179:0.004045:0.003723:0.003723:0.008803:0.004556:0.008198:0.008735:0.004045
high:@0.293763:0.153810:0.321892:0.153810:0.321892:0.139781:0.293763:0.139781:0.008198:0.002688:0.009045:0.008198
Generally high:@0.505457:0.153810:0.600498:0.153810:0.600498:0.139781:0.505457:0.139781:0.011719:0.008735:0.008198:0.008735:0.004045:0.009179:0.002688:0.002688:0.007203:0.003723:0.008198:0.002688:0.009045:0.008198
Beta blockers, alpha blockers, :@0.717150:0.153810:0.916265:0.153810:0.916265:0.139781:0.717150:0.139781:0.007714:0.008735:0.004556:0.009179:0.003723:0.009165:0.002688:0.008803:0.008695:0.006746:0.008735:0.004045:0.005214:0.003723:0.003723:0.009179:0.002688:0.009165:0.008198:0.009179:0.003723:0.009165:0.002688:0.008803:0.008695:0.006746:0.008735:0.004045:0.005214:0.003723:0.003723
other:@0.717150:0.166638:0.751487:0.166638:0.751487:0.152609:0.717150:0.152609:0.008803:0.004556:0.008198:0.008735:0.004045